

**Table 3** Clinical management summary of 13 Ebola virus disease patients treated outside West Africa

Reference	[76]	[76]	[42]	[28, 79, 137]	[78, 79, 82]	[81, 82]	[38]	[25, 77]	[28, 99]	[81]	[81]	[82]	[37]
Demographics													
Gender	M	F	M	M	M	M	M	F	M	F	F	M	M
Age (years)	33	59	36	51	43	42	38	44	33	26	29	44	43
Country of infection	Liberia	Liberia	Sierra Leone	Liberia	Sierra Leone	Liberia	Sierra Leone	Spain	Liberia	USA	USA	Sierra Leone	Sierra Leone
Country providing care	USA	USA	Germany	USA	USA	USA	Germany	Spain	USA	USA	USA	USA	Switzerland
Hospital admission													
Admission date	2 Aug 2014	5 Aug 2014	27 Aug 2014	5 Sep 2014	9 Sep 2014	30 Sep 2014	3 Oct 2014	6 Oct 2014	6 Oct 2014	11 Oct 2014	14 Oct 2014	15 Nov 2014	21 Nov 2014
Days from diagnosis to evacuation	7	10	4	7	2	N/A	5	0	5	N/A	N/A	6	4
Hospital LOS	19	14	30	20	41	8	47	30	16	13	14	3	15
Vital status	Survived	Survived	Survived	Survived	Survived	Died	Survived	Survived	Survived	Survived	Survived	Died	Survived
Critical care therapies													
Central line	N	N	Y	Y	Y	Y	Y	N	Y	Y	N	Y	Y
Vasopressors	N	N	N	N	Y	Y	Y	N	N	N	N	Y	N
Oxygen	Y	Y	Y	Y	Y	Y	Y	Y	N	N	N	Y	N
NIV (d, days)	N	N	Y (8d)	N	N	N	Y (1d)	N	N	N	N	N	N
MV (d, days)	N	N	N	N	Y (17d)	Y (5d)	Y (13d)	N	N	N	N	Y (3d)	N
CRRT (d, days)	N	N	N	N	Y (24d)	Y (5d)	Y (18d)	N	N	N	N	Y (3d)	N
IHD (d, days)	N	N	N	N	N	N	Y (10d)	N	N	N	N	N	N
Experimental therapies													
Convalescent plasma	Y	N	N	Y	Y	N	N	Y	Y	Y	Y	Y	N
ZMapp/ZMab	Y	Y	N	N	N	N	N	Y	N	Y	N	Y	Y
Brincidofovir	N	N	N	N	N	Y	N	N	Y	Y	Y	N	N
Favipiravir	N	N	Y	N	N	N	Y	Y	N	N	N	N	Y
TKM	N	N	Y	Y	Y	N	N	N	N	Y	N	N	N
Other	N/A	N/A	N/A	N/A	N/A	N/A	Amiodarone, FX06	N/A	N/A	N/A	N/A	N/A	N/A

CRRT continuous renal replacement therapy; F female, IHD intermittent hemodialysis, LOS length of stay, M male, MV invasive mechanical ventilation, N/A not available, NIV non-invasive ventilation, TKM TKM-Ebola, small interfering ribonucleic acids (siRNA) produced by Tekmira